Board Certified Oncology Pharmacist BCOP Exam 2026
Latest Comprehensive Study Guide with Practice Questions
Oncology Pharmacy Review Detailed Rationales, Verified
Answers, Success Workbook
The examination covers three major domains: Oncology Diagnosis and Testing
(23%), Therapeutics and Patient Management (49%), and Professional Practice
(28%).
DOMAIN 1: ONCOLOGY DIAGNOSIS AND TESTING — 23%
Questions 1–23
Question 1
A 55-year-old female with newly diagnosed breast cancer has a tumor that is
estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, and HER2-
negative. Which of the following genomic assays would be most appropriate to
guide decisions about adjuvant chemotherapy?
A. BRCA1/2 mutation testing
B. Oncotype DX Breast Recurrence Score
C. FoundationOne CDx
D. PD-L1 immunohistochemistry
Answer: B. Oncotype DX Breast Recurrence Score
Rationale: The Oncotype DX Breast Recurrence Score is a 21-gene expression
assay that predicts the likelihood of distant recurrence in early-stage, ER-positive,
HER2-negative breast cancer and guides adjuvant chemotherapy decisions.
BRCA1/2 testing is for hereditary cancer risk, FoundationOne CDx is a broad
next-generation sequencing panel, and PD-L1 testing guides immunotherapy use.
Question 2
A patient with metastatic non-small cell lung cancer (NSCLC) is found to have an
,EGFR exon 19 deletion. Which of the following is the most appropriate first-line
therapy?
A. Osimertinib
B. Pembrolizumab
C. Carboplatin/pemetrexed
D. Docetaxel
Answer: A. Osimertinib
Rationale: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI)
that is the preferred first-line treatment for patients with EGFR-mutant NSCLC
(exon 19 deletion or L858R). It has superior efficacy compared to first-generation
TKIs and improved central nervous system penetration. Pembrolizumab is for PD-
L1-positive tumors without driver mutations, and chemotherapy is generally
reserved for patients without actionable mutations.
Question 3
Which of the following best describes the mechanism of action of PARP inhibitors
in BRCA-mutated cancers?
A. Inhibition of angiogenesis
B. Synthetic lethality due to defective homologous recombination repair
C. Immune checkpoint blockade
D. Inhibition of topoisomerase II
Answer: B. Synthetic lethality due to defective homologous recombination
repair
Rationale: PARP inhibitors exploit synthetic lethality in tumors with defective
homologous recombination repair (HRR), such as those with BRCA1/2 mutations.
PARP enzymes repair single-strand DNA breaks; when PARP is inhibited, single-
strand breaks accumulate and become double-strand breaks, which cannot be
repaired in BRCA-mutated cells, leading to cell death. This is distinct from
angiogenesis inhibition, immune checkpoint blockade, or topoisomerase inhibition.
Question 4
A patient with chronic myeloid leukemia (CML) is being monitored for response
,to imatinib. Which of the following is the most sensitive test for detecting minimal
residual disease?
A. Complete blood count with differential
B. Bone marrow biopsy with cytogenetics
C. Quantitative reverse transcription polymerase chain reaction (RT-PCR) for
BCR-ABL1
D. Fluorescence in situ hybridization (FISH)
Answer: C. Quantitative reverse transcription polymerase chain reaction
(RT-PCR) for BCR-ABL1
Rationale: Quantitative RT-PCR for BCR-ABL1 is the most sensitive method for
detecting minimal residual disease in CML, with a sensitivity of up to 1 in 100,000
cells. FISH is less sensitive (1 in 100–1,000 cells), and conventional cytogenetics
(bone marrow) is even less sensitive. Complete blood count is not a molecular test.
Question 5
A 65-year-old male with metastatic prostate cancer is found to have a germline
BRCA2 mutation. Which of the following targeted therapies is most appropriate?
A. Abiraterone
B. Enzalutamide
C. Olaparib
D. Docetaxel
Answer: C. Olaparib
Rationale: PARP inhibitors such as olaparib are indicated for patients with
metastatic castration-resistant prostate cancer and germline or somatic BRCA
mutations. Abiraterone and enzalutamide are androgen receptor signaling
inhibitors used regardless of BRCA status. Docetaxel is chemotherapy.
Question 6
Which of the following is a prognostic biomarker in chronic lymphocytic leukemia
(CLL) that predicts a more aggressive disease course?
A. CD20 expression
B. 17p deletion
, C. ZAP-70 methylation
D. Both B and C
Answer: D. Both B and C
Rationale: Both 17p deletion (loss of TP53) and unmutated IGHV (or ZAP-70
expression as a surrogate) are poor prognostic factors in CLL. 17p deletion predicts
resistance to chemotherapy and poor outcomes with chemoimmunotherapy. CD20
expression is a target for rituximab but is not a prognostic marker.
Question 7
A patient with melanoma is being evaluated for BRAF V600E mutation. Which of
the following targeted therapies is indicated for this mutation?
A. Vemurafenib
B. Trametinib
C. Dabrafenib
D. All of the above
Answer: D. All of the above
Rationale: BRAF V600E mutations are targetable with BRAF inhibitors
(vemurafenib, dabrafenib, encorafenib) and MEK inhibitors (trametinib,
cobimetinib, binimetinib). Combination BRAF/MEK inhibition is the standard of
care for BRAF-mutant melanoma due to improved efficacy and reduced resistance.
Question 8
A patient with acute myeloid leukemia (AML) is found to have an FLT3-ITD
mutation. Which of the following agents is most appropriate as part of induction
therapy?
A. Midostaurin
B. Gemtuzumab ozogamicin
C. Venetoclax
D. Enasidenib
Answer: A. Midostaurin
Latest Comprehensive Study Guide with Practice Questions
Oncology Pharmacy Review Detailed Rationales, Verified
Answers, Success Workbook
The examination covers three major domains: Oncology Diagnosis and Testing
(23%), Therapeutics and Patient Management (49%), and Professional Practice
(28%).
DOMAIN 1: ONCOLOGY DIAGNOSIS AND TESTING — 23%
Questions 1–23
Question 1
A 55-year-old female with newly diagnosed breast cancer has a tumor that is
estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, and HER2-
negative. Which of the following genomic assays would be most appropriate to
guide decisions about adjuvant chemotherapy?
A. BRCA1/2 mutation testing
B. Oncotype DX Breast Recurrence Score
C. FoundationOne CDx
D. PD-L1 immunohistochemistry
Answer: B. Oncotype DX Breast Recurrence Score
Rationale: The Oncotype DX Breast Recurrence Score is a 21-gene expression
assay that predicts the likelihood of distant recurrence in early-stage, ER-positive,
HER2-negative breast cancer and guides adjuvant chemotherapy decisions.
BRCA1/2 testing is for hereditary cancer risk, FoundationOne CDx is a broad
next-generation sequencing panel, and PD-L1 testing guides immunotherapy use.
Question 2
A patient with metastatic non-small cell lung cancer (NSCLC) is found to have an
,EGFR exon 19 deletion. Which of the following is the most appropriate first-line
therapy?
A. Osimertinib
B. Pembrolizumab
C. Carboplatin/pemetrexed
D. Docetaxel
Answer: A. Osimertinib
Rationale: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI)
that is the preferred first-line treatment for patients with EGFR-mutant NSCLC
(exon 19 deletion or L858R). It has superior efficacy compared to first-generation
TKIs and improved central nervous system penetration. Pembrolizumab is for PD-
L1-positive tumors without driver mutations, and chemotherapy is generally
reserved for patients without actionable mutations.
Question 3
Which of the following best describes the mechanism of action of PARP inhibitors
in BRCA-mutated cancers?
A. Inhibition of angiogenesis
B. Synthetic lethality due to defective homologous recombination repair
C. Immune checkpoint blockade
D. Inhibition of topoisomerase II
Answer: B. Synthetic lethality due to defective homologous recombination
repair
Rationale: PARP inhibitors exploit synthetic lethality in tumors with defective
homologous recombination repair (HRR), such as those with BRCA1/2 mutations.
PARP enzymes repair single-strand DNA breaks; when PARP is inhibited, single-
strand breaks accumulate and become double-strand breaks, which cannot be
repaired in BRCA-mutated cells, leading to cell death. This is distinct from
angiogenesis inhibition, immune checkpoint blockade, or topoisomerase inhibition.
Question 4
A patient with chronic myeloid leukemia (CML) is being monitored for response
,to imatinib. Which of the following is the most sensitive test for detecting minimal
residual disease?
A. Complete blood count with differential
B. Bone marrow biopsy with cytogenetics
C. Quantitative reverse transcription polymerase chain reaction (RT-PCR) for
BCR-ABL1
D. Fluorescence in situ hybridization (FISH)
Answer: C. Quantitative reverse transcription polymerase chain reaction
(RT-PCR) for BCR-ABL1
Rationale: Quantitative RT-PCR for BCR-ABL1 is the most sensitive method for
detecting minimal residual disease in CML, with a sensitivity of up to 1 in 100,000
cells. FISH is less sensitive (1 in 100–1,000 cells), and conventional cytogenetics
(bone marrow) is even less sensitive. Complete blood count is not a molecular test.
Question 5
A 65-year-old male with metastatic prostate cancer is found to have a germline
BRCA2 mutation. Which of the following targeted therapies is most appropriate?
A. Abiraterone
B. Enzalutamide
C. Olaparib
D. Docetaxel
Answer: C. Olaparib
Rationale: PARP inhibitors such as olaparib are indicated for patients with
metastatic castration-resistant prostate cancer and germline or somatic BRCA
mutations. Abiraterone and enzalutamide are androgen receptor signaling
inhibitors used regardless of BRCA status. Docetaxel is chemotherapy.
Question 6
Which of the following is a prognostic biomarker in chronic lymphocytic leukemia
(CLL) that predicts a more aggressive disease course?
A. CD20 expression
B. 17p deletion
, C. ZAP-70 methylation
D. Both B and C
Answer: D. Both B and C
Rationale: Both 17p deletion (loss of TP53) and unmutated IGHV (or ZAP-70
expression as a surrogate) are poor prognostic factors in CLL. 17p deletion predicts
resistance to chemotherapy and poor outcomes with chemoimmunotherapy. CD20
expression is a target for rituximab but is not a prognostic marker.
Question 7
A patient with melanoma is being evaluated for BRAF V600E mutation. Which of
the following targeted therapies is indicated for this mutation?
A. Vemurafenib
B. Trametinib
C. Dabrafenib
D. All of the above
Answer: D. All of the above
Rationale: BRAF V600E mutations are targetable with BRAF inhibitors
(vemurafenib, dabrafenib, encorafenib) and MEK inhibitors (trametinib,
cobimetinib, binimetinib). Combination BRAF/MEK inhibition is the standard of
care for BRAF-mutant melanoma due to improved efficacy and reduced resistance.
Question 8
A patient with acute myeloid leukemia (AML) is found to have an FLT3-ITD
mutation. Which of the following agents is most appropriate as part of induction
therapy?
A. Midostaurin
B. Gemtuzumab ozogamicin
C. Venetoclax
D. Enasidenib
Answer: A. Midostaurin
